pharmaphorum
JULY 5, 2021
The new deal will assists the company’s focus “on advancing and innovating Parexel to meet our customers’ needs across the evolving clinical development landscape,” he added. ” The deal is subject to the usual conditions, including receipt of various approvals from regulators around the world.
pharmaphorum
SEPTEMBER 8, 2022
However, there is a difference between the two: the toxic payloads of ADCs need to be absorbed into cancer cells, whereas radiopharmaceuticals can still do damage even when only bound to the cancer, and are particularly sensitive to radiation-induced DNA damage. Investment is flowing.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Delveinsight
JULY 29, 2020
British-Swedish pharma company AstraZeneca in collaboration with Jenner Institute (Oxford University) is working on Covid-19 vaccine ChAdOx1 nCoV-19 /AZD1222. Based in Ahmedabad, Zydus Cadila is one of the top most pharma companies in the Indian pharmaceutical industry. Zydus Cadila ( ZyCoV-D ).
Drug Discovery World
OCTOBER 16, 2023
Despite the overall reduction in major pharma R&D centres in the UK, global pharma companies continue to engage with academic and biotech organisations here, particularly in hotspots such as the Golden Triangle, the Northwest, and Scotland, through the strong networks that have been developed between these organisations.
Drug Discovery World
OCTOBER 7, 2022
RA: How can the integration of industry and academia help streamline drug development? . TH : Increasingly, large pharma companies need scale, agility and access to academic partnerships to succeed. It is unsurprising that many pharma companies are increasingly keen to work with academia or academic spin-out.
Pharmaceutical Technology
MAY 26, 2023
Enzymatic DNA production company Touchlight have augmented its DNA production capabilities with a newly announced expansion to its London facilities. Tripling its production capacity, Touchlight can now manufacture 8kg plasmid DNA, a key component for mRNA gene therapies and vaccines.
The Pharma Data
OCTOBER 14, 2020
Priothera will use the funds to progress the clinical development of mocravimod, a modulator of sphingosine 1 phosphate (S1P) receptors, to enhance the curative potential of allogeneic hematopoietic stem cell transplantation (HSCT) for treating AML.
Expert insights. Personalized for you.
64 
Let's personalize your content